Stock Research

Use this section to find out about a particular company or look up a term in our glossary.

GSK - GlaxoSmithKline

GSK
1,743.50
0.52 (+0.03%)
ASK PRICE BID PRICE CHANGE
1,743.50 1,742.50 0.52 (+0.03%)
Volume 550,351
Day's high 1,773.00
Day's low 1,317.50
Today’s open 1,743.50
Prev Close 1,742.00
   

Index: FTSE 100, FTSE 250, FTSE All-Share & techMARK

Sector: Pharmaceuticals & Biotechnology

  • Company URL: http://www.gsk.com
  • Company Profile: GlaxoSmithKline Plc is a healthcare conglomerate. The current company formation is the result of a merger between drug companies GlaxoWellcome and SmithKline Beecham in 2000. GSK's principal pharmaceutical products include medicines or vaccines to treat conditions including asthma, cancer, mental health, diabetes, viruses and digestive problems. Glaxo's consumer health and nutrition divisions owns such brands as Aquafresh toothpast, Panadol tablets, NiQuitin and Nicorette nicotine treatments, and Lucozade and Ribena soft drinks.

GSK Graph

Chart: 1m   3m   6m   Advanced Charting

Set GSK Alert

GSK Trade Tendency

BullBearings trader activity in the last few days with this stock

Buying: 61%

Selling: 39%

Recent trades by BullBearings members
TRADE QTY. PRICE DATE
BUY (auto) 700 1745.5p 24/05/13 07:15
BUY 285 1741.5p 23/05/13 12:45
BUY 84 1746p 23/05/13 12:21
SELL 575 1736.5p 23/05/13 10:36
SELL 815 1747.5p 23/05/13 08:52

Popular stocks in GSK's sector

Pharmaceuticals & Biotechnology
EPIC CODE ASK PRICE CHANGE  
ATD 0.60p (-23.08%) TRADE
AKT 0.45p (-6.67%) TRADE
GMX 1.00p (+46.67%) TRADE
CAT 0.96p (+0.05%) TRADE
ABH 0.06p (-9.09%) TRADE
OXB 2.40p (-3.16%) TRADE
VER 23.00p (-1.12%) TRADE
AZN 3,443.50p (+0.47%) TRADE
SHP 2,136.00p (+0.09%) TRADE
ASM 1.75p (-1.49%) TRADE
BGC 389.50p (+3.78%) TRADE

News & Reports referencing GSK

Wednesday broker round-up UPDATE

Afferro Mining: Panmure Gordon reduces target price from 279p to 100p, while keeping its buy recommendation.

2 days ago

Glaxo hit by US regulatory delay

GlaxoSmithKline has been hit by a delay to one of the six key drugs on which it was awaiting regulatory decisions this year.

3 weeks ago

Tuesday broker round-up UPDATE

Aberdeeen Asset Management: Morgan Stanley raises target price from 478p to 548p retaining an overweight rating. Bank of America ups target price from 455p to 475p and leaves its neutral rating unchanged. JP Morgan increases target price from 532p to 573p and maintains an overweight rating. Citigroup ups target price from 455p to 470p, while its neutral rating remains unchanged. UBS moves target price from 500p to 520p and retains a buy recommendation. Jefferies revises target price from 420p to 475p and keeps a hold recommendation.

3 weeks ago

GlaxoSmithKline submits application for COPD drug in EU

GlaxoSmithKline (GSK) has submitted a regulatory application in the EU for umeclidinium monotherapy, an investigative once-daily medicine used in patients with chrinic obstructive pulmonary disease (COPD).

4 weeks ago

GSK advances on plans to sell Lucozade and Ribena brands, Q1 results disappoint

FTSE 100-listed pharmaceuticals group GlaxoSmithKline (GSK) has announced plans to sell its Lucozade and Ribena brands during its less-than-impressive first quarter results, which showed a two per cent contraction in group sales.

4 weeks ago

Morning Traders' notes

USD strengthened after Ben Bernanke's comments during Q&A session

Daily global markets overview with the overnight activity and what can be expected in the markets today. Information straight from the traders’ desks. Insights on commodities, equities, stocks and forex currencies.

Which trading game would you like to trade with ?